MIRM
Mirum Pharmaceuticals IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$5.77B
P/E Ratio
—
EPS
$-0.47
Beta
0.52
52W High
$109.28
52W Low
$37.33
50-Day MA
$96.16
200-Day MA
$75.45
Dividend Yield
—
Profit Margin
-4.48%
Forward P/E
2000.00
PEG Ratio
—
About Mirum Pharmaceuticals Inc
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, is focused on the development and commercialization of an advanced line of novel therapies for debilitating liver diseases. The company is headquartered in Foster City, California.
Fundamentals
| Revenue (TTM) | $521.31M |
| Gross Profit (TTM) | $421.07M |
| EBITDA | $2.11M |
| Operating Margin | -3.07% |
| Return on Equity | -8.65% |
| Return on Assets | -1.83% |
| Revenue/Share (TTM) | $10.38 |
| Book Value | $6.06 |
| Price-to-Book | 18.05 |
| Price-to-Sales (TTM) | 11.07 |
| EV/Revenue | 10.78 |
| EV/EBITDA | 326.47 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 49.80% |
| Shares Outstanding | $60.34M |
| Float | $52.43M |
| % Insiders | 1.33% |
| % Institutions | 104.89% |
Analyst Ratings
Consensus ($125.36 target)
3
Strong Buy8
BuyData last updated: 4/8/2026